Matrix metalloproteinases and their multiple roles in n

Lancet Neurology, The
8, 205-216
DOI: 10.1016/s1474-4422(09)70016-x

Citation Report

#	Article	IF	Citations
1	Inflammatory Proprotein Convertase-Matrix Metalloproteinase Proteolytic Pathway in Antigen-presenting Cells as a Step to Autoimmune Multiple Sclerosis. Journal of Biological Chemistry, 2009, 284, 30615-30626.	3.4	39
2	Contributions of Matrix Metalloproteinases to Neural Plasticity, Habituation, Associative Learning and Drug Addiction. Neural Plasticity, 2009, 2009, 1-12.	2.2	68
3	MMP-9, a Potential Target for Cerebral Ischemic Treatment. Current Neuropharmacology, 2009, 7, 269-275.	2.9	80
4	Neurovascular mechanisms and bloodâ€“brain barrier disorder in Alzheimerâ€™s disease. Acta Neuropathologica, 2009, 118, 103-113.	7.7	769
5	Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2009, 66, 3923-3935.	5.4	34
7	The bloodâ€“brain barrier in neurodegenerative disease: a rhetorical perspective. Journal of Neurochemistry, 2009, 111, 291-314.	3.9	196
8	From the â€œlittle brainâ€•gastrointestinal infection to the â€œbig brainâ€•neuroinflammation: A proposed fast axonal transport pathway involved in multiple sclerosis. Medical Hypotheses, 2009, 73, 781-787.	1.5	31
9	Increased MMP-3 and CTGF expression during lipopolysaccharide-induced dopaminergic neurodegeneration. Neuroscience Letters, 2009, 460, 27-31.	2.1	26
10	Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1â€“42 levels. Neuroscience Letters, 2009, 466, 135-138.	2.1	35
11	Endogenous Agmatine Inhibits Cerebral Vascular Matrix Metalloproteinases Expression by Regulating Activating Transcription Factor 3 and Endothelial Nitric Oxide Synthesis. Current Neurovascular Research, 2010, 7, 201-212.	1.1	26
12	Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. Current Opinion in Neurology, 2010, 23, 293-299.	3.6	293
13	Update of human and mouse matrix metalloproteinase families. Human Genomics, 2010, 4, 194-201.	2.9	84
14	Exploring Neuroprotective Drug Therapies for Intracerebral Hemorrhage. Journal of Pharmacological Sciences, 2010, 114, 366-378.	2.5	66
15	Metalloproteinase alterations in the bone marrow of ALS patients. Journal of Molecular Medicine, 2010, 88, 553-564.	3.9	30
16	Mitochondrial DNA Mutation-Elicited Oxidative Stress, Oxidative Damage, and Altered Gene Expression in Cultured Cells of Patients with MERRF Syndrome. Molecular Neurobiology, 2010, 41, 256-266.	4.0	77
17	Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathology International, 2010, 60, 477-496.	1.3	227
18	Regulation of the bloodâ€“brain barrier integrity by pericytes via matrix metalloproteinases mediated activation of vascular endothelial growth factor in vitro. Brain Research, 2010, 1347, 1-10.	2.2	83
19	Type IV collagen induces expression of thrombospondinâ€1 that is mediated by integrin Î±1Î²1 in astrocytes. Glia, 2010, 58, 755-767.	4.9	26

#	Article	IF	Citations
20	Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. European Journal of Neurology, 2010, 17, 226-231.	3.3	70
21	Matrix Metalloproteinase-9 Mediates Hypoxia-Induced Vascular Leakage in the Brain via Tight Junction Rearrangement. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 837-848.	4.3	282
22	Hemoglobin-Induced Oxidative Stress Contributes to Matrix Metalloproteinase Activation and Bloodâ€“Brain Barrier Dysfunction in vivo. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 1939-1950.	4.3	126
23	Discovery proteomics: application to HIV infection. Journal of Clinical Pathology, 2010, 63, 285-287.	2.0	2
24	Metzincin Proteases and Their Inhibitors: Foes or Friends in Nervous System Physiology?. Journal of Neuroscience, 2010, 30, 15337-15357.	3.6	204
25	Matrix Metalloproteinase 2 (MMP-2) Degrades Soluble Vasculotropic Amyloid-Î² E22Q and L34V Mutants, Delaying Their Toxicity for Human Brain Microvascular Endothelial Cells. Journal of Biological Chemistry, 2010, 285, 27144-27158.	3.4	43
26	Ectodomain Shedding and Regulated Intracellular Proteolysis in the Central Nervous System. Central Nervous System Agents in Medicinal Chemistry, 2010, 10, 337-359.	1.1	17
27	Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Critical Reviews in Biochemistry and Molecular Biology, 2010, 45, 351-423.	5.2	263
28	Theoretic, Experimental, Clinical Bases of the Water Oscillator Hypothesis in Near-Infrared Photobiomodulation. Photomedicine and Laser Surgery, 2010, 28, S-41-S-52.	2.0	35
29	Proteomic analysis of astrocytic secretion that regulates neurogenesis using quantitative amine-specific isobaric tagging. Biochemical and Biophysical Research Communications, 2010, 391, 1187-1191.	2.1	9
30	The Science of Stroke: Mechanisms in Search of Treatments. Neuron, 2010, 67, 181-198.	8.1	1,628
31	Matrix metalloproteinase-dependent shedding of intercellular adhesion molecule-5 occurs with long-term potentiation. Neuroscience, 2010, 166, 508-521.	2.3	107
32	Distribution of a novel binding site for angiotensins II and III in mouse tissues. Regulatory Peptides, 2010, 162, 5-11.	1.9	9
33	Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2010, 2, 20.	6.2	78
34	Mesoporous silicon photonic crystal microparticles: towards single-cell optical biosensors. Faraday Discussions, 2011, 149, 301-317.	3.2	52
35	The executioners sing a new song: killer caspases activate microglia. Cell Death and Differentiation, 2011, 18, 1679-1691.	11.2	47
36	Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Reviews in Molecular Medicine, 2011, 13, e19.	3.9	168
37	Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nature Reviews Neuroscience, 2011, 12, 723-738.	10.2	2,254

#	Article	IF	Citations
38	Cerebrospinal Fluid Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Combination with Subcortical and Cortical Biomarkers in Vascular Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 665-676.	2.6	150
39	The impact of pericytes on the bloodâ€“brain barrier integrity depends critically on the pericyte differentiation stage. International Journal of Biochemistry and Cell Biology, 2011, 43, 1284-1293.	2.8	105
40	Bloodâ€“Brain Barrier Breakdown in Acute and Chronic Cerebrovascular Disease. Stroke, 2011, 42, 3323-3328.	2.0	620
41	Relations of Blood Inflammatory Marker Levels With Cerebral Microbleeds. Stroke, 2011, 42, 3202-3206.	2.0	85
42	Doxycycline could aggravate the absence-like epileptic seizures of WAG/Rij rats via matrix metalloproteinase inhibition. Neurochemistry International, 2011, 59, 563-566.	3.8	7
43	Matrix metalloproteinases 2 and 9 in the cochlea: expression and activity after aminoglycoside exposition. Neuroscience, 2011, 181, 28-39.	2.3	19
44	Matrix Metalloproteinases and Their Tissue Inhibitors in Cuprizone-Induced Demyelination and Remyelination of Brain White and Gray Matter. Journal of Neuropathology and Experimental Neurology, 2011, 70, 758-769.	1.7	40
45	Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype. European Journal of Neuroscience, 2011, 34, 3-11.	2.6	276
46	Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse. European Journal of Neuroscience, 2011, 34, 1085-1092.	2.6	41
47	Review: Sporadic cerebral amyloid angiopathy. Neuropathology and Applied Neurobiology, 2011, 37, 75-93.	3.2	285
48	Role of matrix metalloproteinaseâ€9 (MMPâ€9) in striatal bloodâ€“brain barrier disruption in a 3â€nitropropionic acid model of Huntington's disease. Neuropathology and Applied Neurobiology, 2011, 37, 525-537.	3.2	41
49	Matrix metalloproteinaseâ€9 and intercellular adhesion molecule 1 are powerful staging markers for human African trypanosomiasis. Tropical Medicine and International Health, 2011, 16, 119-126.	2.3	33
50	Increased cerebral matrix metalloproteaseâ€9 activity is associated with compromised recovery in the diabetic db/db mouse following a stroke. Journal of Neurochemistry, 2011, 119, 1029-1040.	3.9	66
51	Guide to Receptors and Channels (GRAC), 5th edition. British Journal of Pharmacology, 2011, 164, S1-324.	5.4	827
52	Consultants. British Journal of Pharmacology, 2011, 164, S3-S3.	5.4	10
53	G PROTEINâ€COUPLED RECEPTORS. British Journal of Pharmacology, 2011, 164, S5.	5.4	16
54	LIGANDâ€GATED ION CHANNELS. British Journal of Pharmacology, 2011, 164, S115.	5.4	13
55	ION CHANNELS. British Journal of Pharmacology, 2011, 164, S137.	5.4	22

#	Article	IF	Citations
56	NUCLEAR RECEPTORS. British Journal of Pharmacology, 2011, 164, S175-S188.	5.4	0
57	CATALYTIC RECEPTORS. British Journal of Pharmacology, 2011, 164, S189-S212.	5.4	1
58	TRANSPORTERS. British Journal of Pharmacology, 2011, 164, S213.	5.4	2
60	EMMPRIN levels in serum of patients with amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 2011, 124, 424-428.	2.1	6
61	Engaging neuroscience to advance translational research in brain barrier biology. Nature Reviews Neuroscience, 2011, 12, 169-182.	10.2	508
62	OXPHOS toxicogenomics and Parkinson's disease. Mutation Research - Reviews in Mutation Research, 2011, 728, 98-106.	5.5	23
63	Altered matrix metalloproteinases and tissue inhibitors of metalloproteinases in embryos from diabetic rats during early organogenesis. Reproductive Toxicology, 2011, 32, 449-462.	2.9	14
64	Matrix metalloproteinase-9 controls proliferation of NG2+ progenitor cells immediately after spinal cord injury. Experimental Neurology, 2011, 231, 236-246.	4.1	37
65	Regulation of matrix metalloproteinase 2 by oligomeric amyloid Î² protein. Brain Research, 2011, 1387, 141-148.	2.2	51
66	Neurotoxic factors released by stimulated human monocytes and THP-1 cells. Brain Research, 2011, 1400, 99-111.	2.2	15
67	Solulin reduces infarct volume and regulates gene-expression in transient middle cerebral artery occlusion in rats. BMC Neuroscience, 2011, 12, 113.	1.9	28
68	Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-Î±, releasing matrix metalloproteinase-9 and migrating in vitro. Journal of Neuroinflammation, 2011, 8, 106.	7.2	150
69	Altered expression of tissue remodeling genes in a mouse model of acute allergic rhinitis. International Forum of Allergy and Rhinology, 2011, 1, 262-267.	2.8	12
70	Matrix Metalloproteinases Are Associated With Increased Bloodâ€“Brain Barrier Opening in Vascular Cognitive Impairment. Stroke, 2011, 42, 1345-1350.	2.0	136
71	Bloodâ€“Brain Barrier Permeability Abnormalities in Vascular Cognitive Impairment. Stroke, 2011, 42, 2158-2163.	2.0	209
72	Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases. Current Molecular Medicine, 2011, 11, 696-707.	1.3	45
73	Zinc Metalloproteinases and Amyloid Beta-Peptide Metabolism: The Positive Side of Proteolysis in Alzheimer's Disease. Biochemistry Research International, 2011, 2011, 1-13.	3.3	27
74	Status of research on MMPs in India. Expert Opinion on Therapeutic Targets, 2011, 15, 715-728.	3.4	6

#	Article	IF	Citations
75	BACE1 Dependent Neuregulin Processing: Review. Current Alzheimer Research, 2012, 9, 178-183.	1.4	62
76	Suppression of MMP-9 Expression in Brain Microvascular Endothelial Cells (BMVEC) Using a Gold Nanorod (GNR)-siRNA Nanoplex. Immunological Investigations, 2012, 41, 337-355.	2.0	27
77	Tissue-Specific Functional Networks for Prioritizing Phenotype and Disease Genes. PLoS Computational Biology, 2012, 8, e1002694.	3.2	137
78	Matrix Metalloproteinase-2 and Epidermal Growth Factor are Decreased in Platelets of Alzheimer Patients. Current Alzheimer Research, 2012, 9, 982-989.	1.4	27
79	The blood-brain barrier is disrupted in a mouse model of infantile neuronal ceroid lipofuscinosis: amelioration by resveratrol. Human Molecular Genetics, 2012, 21, 2233-2244.	2.9	52
80	Peptide-Based Selective Inhibitors of Matrix Metalloproteinase-Mediated Activities. Molecules, 2012, 17, 14230-14248.	3.8	53
81	Volatile Anesthetics Reduce Biochemical Markers of Brain Injury and Brain Magnesium Disorders in Patients Undergoing Coronary Artery Bypass Graft Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2012, 26, 395-402.	1.3	26
82	Matrix metalloproteinaseâ€3 in the central nervous system: a look on the bright side. Journal of Neurochemistry, 2012, 123, 203-216.	3.9	88
83	Inflammatory events at bloodâ€“brain barrier in neuroinflammatory and neurodegenerative disorders: Implications for clinical disease. Epilepsia, 2012, 53, 45-52.	5.1	97
84	Cannabidiol affects the expression of genes involved in zinc homeostasis in BV-2 microglial cells. Neurochemistry International, 2012, 61, 923-930.	3.8	28
85	Multiplexing and multivariate analysis in neurodegeneration. Methods, 2012, 56, 464-470.	3.8	11
86	Matrix metalloproteinases in skeletal muscles: Friends or foes?. Neurobiology of Disease, 2012, 48, 508-518.	4.4	58
87	HIV-1 Tat-induced cerebrovascular toxicity is enhanced in mice with amyloid deposits. Neurobiology of Aging, 2012, 33, 1579-1590.	3.1	14
88	Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats. Neuroscience, 2012, 221, 140-150.	2.3	74
89	Fetal stress and programming of hypoxic/ischemic-sensitive phenotype in the neonatal brain: Mechanisms and possible interventions. Progress in Neurobiology, 2012, 98, 145-165.	5.7	103
90	Chemical Biology for Understanding Matrix Metalloproteinase Function. ChemBioChem, 2012, 13, 2002-2020.	2.6	46
91	Interactions between the extracellular matrix and inflammation during viral myocarditis. Immunobiology, 2012, 217, 503-510.	1.9	23
92	Personality traits and the R668Q polymorphism located in the MMP-9 gene. Behavioural Brain Research, 2012, 228, 232-235.	2.2	6

#	Article	IF	Citations
93	Albumin induces upregulation of matrix metalloproteinase-9 in astrocytes via MAPK and reactive oxygen species-dependent pathways. Journal of Neuroinflammation, 2012, 9, 68.	7.2	72
94	Strain differences in the effects of chronic corticosterone exposure in the hippocampus. Neuroscience, 2012, 222, 269-280.	2.3	27
95	Baclofen influences acquisition and MMP-2, MMP-9 levels in the hippocampus of rats after hypoxia. Pharmacological Reports, 2012, 64, 536-545.	3.3	5
96	Amyloid-Î² Contributes to Bloodâ€“Brain Barrier Leakage in Transgenic Human Amyloid Precursor Protein Mice and in Humans With Cerebral Amyloid Angiopathy. Stroke, 2012, 43, 514-523.	2.0	201
97	Biomarkers and location of atherosclerosis: Matrix metalloproteinase-2 may be related to intracranial atherosclerosis. Atherosclerosis, 2012, 223, 442-447.	0.8	24
98	Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. Molecular Neurodegeneration, 2012, 7, 21.	10.8	93
99	Changes in pain and insulin-like growth factor 1 in fibromyalgia during exercise: the involvement of cerebrospinal inflammatory factors and neuropeptides. Arthritis Research and Therapy, 2012, 14, R162.	3.5	45
100	Metabolic and immune risk factors for dementia and their modification by flavonoids: New targets for the prevention of cognitive impairment?. Nutrition and Aging (Amsterdam, Netherlands), 2012, 1, 69-88.	0.3	3
101	Melatonin inhibits IL1Î²-induced MMP9 expression and activity in human umbilical vein endothelial cells by suppressing NF-ÎºB activation. Journal of Endocrinology, 2012, 214, 145-153.	2.6	68
102	Degrading Epilepsy: The Role of Extracellular Proteases and the Extracellular Matrix. Epilepsy Currents, 2012, 12, 118-120.	0.8	1
103	The yak genome and adaptation to life at high altitude. Nature Genetics, 2012, 44, 946-949.	21.4	708
104	Excitatory and Mitogenic Signaling in Cell Death, Bloodâ€“brain Barrier Breakdown, and BBB Repair after Intracerebral Hemorrhage. Translational Stroke Research, 2012, 3, 62-69.	4.2	25
105	The Classification of Microglial Activation Phenotypes on Neurodegeneration and Regeneration in Alzheimerâ€™s Disease Brain. Archivum Immunologiae Et Therapiae Experimentalis, 2012, 60, 251-266.	2.3	323
106	Genetic Variations in the ADAMTS12 Gene are Associated with Schizophrenia in Puerto Rican Patients of Spanish Descent. NeuroMolecular Medicine, 2012, 14, 53-64.	3.4	13
107	Matrix metalloproteinase-12 deficiency ameliorates the clinical course and demyelination in Theilerâ€™s murine encephalomyelitis. Acta Neuropathologica, 2012, 124, 127-142.	7.7	48
108	Cells, biomarkers, and postâ€traumatic stress disorder: evidence for peripheral involvement in a central disease. Journal of Neurochemistry, 2012, 120, 26-36.	3.9	56
109	Increased expression of matrix metalloproteinase 9 in cortical lesions from patients with focal cortical dysplasia type IIb and tuberous sclerosis complex. Brain Research, 2012, 1453, 46-55.	2.2	43
110	Involvement of Perineuronal and Perisynaptic Extracellular Matrix in Alzheimer's Disease Neuropathology. Brain Pathology, 2012, 22, 547-561.	4.1	124

#	Article	IF	Citations
111	Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. , 2012, 133, 257-279.		98
112	Dynamics of expression patterns of AQP4, dystroglycan, agrin and matrix metalloproteinases in human glioblastoma. Cell and Tissue Research, 2012, 347, 429-441.	2.9	60
113	Effects of oxidative stress on amyloid precursor protein processing in rat and human platelets. Platelets, 2013, 24, 26-36.	2.3	20
114	Fluorometric immunocapture assay for the specific measurement of matrix metalloproteinase-9 activity in biological samples: application to brain and plasma from rats with ischemic stroke. Molecular Brain, 2013, 6, 14.	2.6	28
115	Matrix Metalloproteinase-2 and Metalloproteinase-9 Activities are Associated with Bloodâ€“Brain Barrier Dysfunction in an Animal Model of Severe Sepsis. Molecular Neurobiology, 2013, 48, 62-70.	4.0	91
116	Mitochondrial impairment induced by 3-nitropropionic acid is enhanced by endogenous metalloprotease activity inhibition in cultured rat striatal neurons. Neuroscience Letters, 2013, 546, 16-20.	2.1	3
117	Interrelationship between activation of matrix metalloproteinases and mitochondrial dysfunction in the development of diabetic retinopathy. Biochemical and Biophysical Research Communications, 2013, 438, 760-764.	2.1	41
118	Emerging Understanding of Roles for Arterioles in Inflammation. Microcirculation, 2013, 20, 679-692.	1.8	10
119	Proteases: Structure and Function. , 2013, , .		31
120	Targeting the neural extracellular matrix in neurological disorders. Neuroscience, 2013, 253, 194-213.	2.3	198
121	Gold-nanoparticle-based biosensors for detection of enzyme activity. Trends in Pharmacological Sciences, 2013, 34, 497-507.	8.7	146
122	Proteolytic Assays on Quantum-Dot-Modified Paper Substrates Using Simple Optical Readout Platforms. Analytical Chemistry, 2013, 85, 8817-8825.	6.5	73
123	Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview. Acta Neurologica Belgica, 2013, 113, 381-390.	1.1	30
124	The Concise Guide to <scp>PHARMACOLOGY</scp> 2013/14: Enzymes. British Journal of Pharmacology, 2013, 170, 1797-1867.	5.4	416
125	Critical role of calpain in spinal cord degeneration in <scp>P</scp>arkinson's disease. Journal of Neurochemistry, 2013, 127, 880-890.	3.9	41
126	Protective Reactivity and Alteration of the Brain Tissue in Alcoholics Evidenced by SOD1, MMP9 Immunohistochemistry, and Electron Microscopy. Ultrastructural Pathology, 2013, 37, 346-355.	0.9	7
127	Oleuropein, an Anti-oxidant Polyphenol Constituent of Olive Promotes Î±-Secretase Cleavage of the Amyloid Precursor Protein (AÎ²PP). Cellular and Molecular Neurobiology, 2013, 33, 147-154.	3.3	61
128	Pediatric Ischemic Stroke: Acute Management and Areas of Research. Journal of Pediatrics, 2013, 162, 227-235.e1.	1.8	7

#	Article	IF	Citations
129	Nanoparticle and liposome formulations of doxycycline: Transport properties through Caco-2 cell line and effects on matrix metalloproteinase secretion. Biomedicine and Pharmacotherapy, 2013, 67, 459-467.	5.6	23
130	Microbleeds in ischemic stroke are associated with lower serum adiponectin and higher soluble E-selectin levels. Journal of the Neurological Sciences, 2013, 334, 83-87.	0.6	24
131	INtensive versus Standard Ambulatory Blood Pressure Lowering to Prevent Functional DeclINe In The ElderlY (INFINITY). American Heart Journal, 2013, 165, 258-265.e1.	2.7	38
132	Matrix metalloproteinase-2 and -9 as promising benefactors in development, plasticity and repair of the nervous system. Progress in Neurobiology, 2013, 105, 60-78.	5.7	141
133	A New Face for Old Antibiotics: Tetracyclines in Treatment of Amyloidoses. Journal of Medicinal Chemistry, 2013, 56, 5987-6006.	6.4	76
134	Matrix metalloproteinase (MMP)-2 gene polymorphisms affect circulating MMP-2 levels in patients with migraine with aura. Gene, 2013, 512, 35-40.	2.2	35
135	Psychostimulant Abuse and Neuroinflammation: Emerging Evidence of Their Interconnection. Neurotoxicity Research, 2013, 23, 174-188.	2.7	159
136	The protective effect of berberine against neuronal damage by inhibiting matrix metalloproteinase-9 and laminin degradation in experimental autoimmune encephalomyelitis. Neurological Research, 2013, 35, 360-368.	1.3	34
137	The Bloodâ€“Brain Barrier: An Introduction to Its Structure and Function. Topics in Medicinal Chemistry, 2013, , 1-20.	0.8	4
138	Inhibition of Proteasomal Glucocorticoid Receptor Degradation Restores Dexamethasone-Mediated Stabilization of the Bloodâ€“Brain Barrier After Traumatic Brain Injury*. Critical Care Medicine, 2013, 41, 1305-1315.	0.9	49
139	Xiao-Xu-MingDecoction Protects against Blood-Brain Barrier Disruption and Neurological Injury Induced by Cerebral Ischemia and Reperfusion in Rats. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-12.	1.2	17
140	Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with moderate and severe traumatic brain injury. Neurology India, 2013, 61, 606.	0.4	17
141	Impact of Manganese Neurotoxicity on MMP-9 Production and Superoxide Dismutase Activity in Rat Primary Astrocytes. Effect of Resveratrol and Therapeutical Implications for the Treatment of CNS Diseases. Toxicological Sciences, 2013, 135, 218-228.	3.1	35
142	Stromal cell-derived factor-1 and its receptor CXCR4 in adult neurogenesis after cerebral ischemia. Restorative Neurology and Neuroscience, 2013, 31, 239-251.	0.7	56
143	Hypertension. Hypertension, 2013, 62, 810-817.	2.7	287
144	TRIF-Mediated TLR3 and TLR4 Signaling Is Negatively Regulated by ADAM15. Journal of Immunology, 2013, 190, 2217-2228.	0.8	36
145	Therapeutic strategies to attenuate hemorrhagic transformation after tissue plasminogen activator treatment for acute ischemic stroke. Neurology and Clinical Neuroscience, 2013, 1, 201-208.	0.4	5
146	A R_{2p}/R_{1p} Ratiometric Procedure to Assess Matrix Metalloproteinaseâ€2 Activity by Magnetic Resonance Imaging. Angewandte Chemie - International Edition, 2013, 52, 3926-3930.	13.8	30

#	Article	IF	Citations
148	tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRPs. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2013, 7, 65-76.	0.6	15
149	Mechanical stretching induces matrix metalloproteinase-2 expression in rat retinal glial (MÃ¼ller) cells. NeuroReport, 2013, 24, 224-228.	1.2	16
150	MMPs in the Trabecular Meshwork: Promising Targets for Future Glaucoma Therapies?. , 2013, 54, 7756.		87
151	Niaspan Attenuates the Adverse Effects of Bone Marrow Stromal Cell Treatment of Stroke in Type One Diabetic Rats. PLoS ONE, 2013, 8, e81199.	2.5	24
152	Therapeutic Interventions in Alzheimer Disease. , 0, , .		8
153	Src Family Kinases in Intracerebral Hemorrhage. , 0, , .		0
154	Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF-Î± Release from Activated Microglia and TNF-Î± Converting Enzyme Activity. Biomolecules and Therapeutics, 2014, 22, 414-419.	2.4	17
155	On the Structure and functions of gelatinase B/Matrix metalloproteinase-9 in neuroinflammation. Progress in Brain Research, 2014, 214, 193-206.	1.4	54
156	Endogenous and synthetic MMP inhibitors in CNS physiopathology. Progress in Brain Research, 2014, 214, 313-351.	1.4	39
157	Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS). Journal of Neural Transmission, 2014, 121, 1387-1397.	2.8	23
158	Inhibition of matrix metalloproteinases attenuates brain damage in experimental meningococcal meningitis. BMC Infectious Diseases, 2014, 14, 726.	2.9	29
159	Monitoring the Biomolecular Interactions and the Activity of Zn-Containing Enzymes Involved in Conformational Diseases. Advances in Protein Chemistry and Structural Biology, 2014, 97, 115-142.	2.3	5
160	Function of microglia and macrophages in secondary damage after spinal cord injury. Neural Regeneration Research, 2014, 9, 1787.	3.0	212
161	Tanshinone IIA reduces the risk of Alzheimerâ€™s disease by inhibiting iNOS, MMP-2 and NF-Î²Bp65 transcription and translation in the temporal lobes of rat models of Alzheimerâ€™s disease. Molecular Medicine Reports, 2014, 10, 689-694.	2.4	67
162	Matrix metalloproteinases and epileptogenesis. Molecular and Cellular Pediatrics, 2014, 1, 6.	1.8	24
163	Bloodâ€“brain barrier and traumatic brain injury. Journal of Neuroscience Research, 2014, 92, 141-147.	2.9	113
164	Genetic Variations within Metalloproteinases Impact on the Prophylaxis of Depressive Phases in Bipolar Patients. Neuropsychobiology, 2014, 69, 76-82.	1.9	6
165	MMPs in the Neuroretina and Optic Nerve: Modulators of Glaucoma Pathogenesis and Repair?. , 2014, 55, 1953.		56

#	Article	IF	Citations
166	Spontaneous white matter damage, cognitive decline and neuroinflammation in middle-aged hypertensive rats: an animal model of early-stage cerebral small vessel disease. Acta Neuropathologica Communications, 2014, 2, 169.	5.2	130
167	3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) disrupts blood-brain barrier integrity through a mechanism involving P2X7 receptors. International Journal of Neuropsychopharmacology, 2014, 17, 1243-1255.	2.1	21
168	Circadian angiogenesis. Biomolecular Concepts, 2014, 5, 245-256.	2.2	19
169	Coadministration of Branched-Chain Amino Acids and Lipopolysaccharide Causes Matrix Metalloproteinase Activation and Bloodâ€“Brain Barrier Breakdown. Molecular Neurobiology, 2014, 50, 358-367.	4.0	16
170	High-Density Lipoproteins and Cerebrovascular Integrity in Alzheimerâ€™s Disease. Cell Metabolism, 2014, 19, 574-591.	16.2	76
171	Analysis of Matrix Metallo-Proteases and the Plasminogen System in Mild Cognitive Impairment and Alzheimer's Disease Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2014, 40, 667-678.	2.6	55
172	The role of macrophage phenotype in vascularization of tissue engineering scaffolds. Biomaterials, 2014, 35, 4477-4488.	11.4	728
173	Vitamin D as a Potential Therapy in Amyotrophic Lateral Sclerosis. CNS Neuroscience and Therapeutics, 2014, 20, 101-111.	3.9	44
174	Concentrations of Matrix Metalloproteinases and their Tissue Inhibitors in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 40, 351-357.	2.6	42
175	Disturbance in Venous Outflow From the Cerebral Circulation Intensifies the Release of Blood-Brain Barrier Injury Biomarkers in Patients Undergoing Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2014, 28, 328-335.	1.3	19
176	Ten years of proteomics in multiple sclerosis. Proteomics, 2014, 14, 467-480.	2.2	31
177	Cellâ€specific bloodâ€“brain barrier regulation in health and disease: a focus on hypoxia. British Journal of Pharmacology, 2014, 171, 1210-1230.	5.4	129
178	Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the tumors of central nervous system (CNS). Journal of Neural Transmission, 2014, 121, 469-477.	2.8	9
179	Metal complexes and metalloproteases: targeting conformational diseases. Metallomics, 2014, 6, 1346-1357.	2.4	28
180	Effects of progesterone vs. dexamethasone on brain oedema and inflammatory responses following experimental brain resection. Brain Injury, 2014, 28, 1594-1601.	1.2	25
181	In Vitro Cerebrovascular Modeling in the 21st Century: Current and Prospective Technologies. Pharmaceutical Research, 2014, 31, 3229-3250.	3.5	41
182	Neuroinflammation and Neurodegeneration. , 2014, , .		11
183	Matrix Metalloproteinase-8 Plays a Pivotal Role in Neuroinflammation by Modulating TNF-Î± Activation. Journal of Immunology, 2014, 193, 2384-2393.	0.8	63

#	Article	IF	Citations
184	MMP-9 Inhibitor SB-3CT Attenuates Behavioral Impairments and Hippocampal Loss after Traumatic Brain Injury in Rat. Journal of Neurotrauma, 2014, 31, 1225-1234.	3.4	43
185	Amyloid-beta (25â€“35) peptide induces the release of pro-matrix metalloprotease 9 (pro-MMP-9) from human neutrophils. Molecular and Cellular Biochemistry, 2014, 397, 117-123.	3.1	12
186	Efficiency of Protease-Activatable Virus Nanonodes Tuned Through Incorporation of Wild-Type Capsid Subunits. Cellular and Molecular Bioengineering, 2014, 7, 334-343.	2.1	16
187	Inhibition of MMP-2 but not MMP-9 Influences Inner Ear Spiral Ganglion Neurons In Vitro. Cellular and Molecular Neurobiology, 2014, 34, 1011-1021.	3.3	5
188	Serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in patients with tick-borne encephalitis. Journal of Infection, 2014, 68, 165-169.	3.3	22
189	Multiplexed Homogeneous Assays of Proteolytic Activity Using a Smartphone and Quantum Dots. Analytical Chemistry, 2014, 86, 3195-3202.	6.5	143
190	The importance of temperature on the neurovascular unit. Early Human Development, 2014, 90, 713-717.	1.8	6
191	PGE2/EP4 signaling in peripheral immune cells promotes development of experimental autoimmune encephalomyelitis. Biochemical Pharmacology, 2014, 87, 625-635.	4.4	25
192	Interleukin-1Î² induces an inflammatory response and the breakdown of the endothelial cell layer in an improved human THBMEC-based in vitro bloodâ€“brain barrier model. Journal of Neuroscience Methods, 2014, 228, 35-45.	2.5	70
193	Statins in neurological disorders: An overview and update. Pharmacological Research, 2014, 88, 74-83.	7.1	65
194	Polyphenols from the stems of Morus alba and their inhibitory activity against nitric oxide production by lipopolysaccharide-activated microglia. FÃ¬toterapÃ¬Ã¢, 2014, 97, 253-260.	2.2	28
195	Recent Updates on Subcortical Ischemic Vascular Dementia. Journal of Stroke, 2014, 16, 18.	3.2	78
197	Role of Rho kinase in lysophosphatidic acid-induced altering of blood-brain barrier permeability. International Journal of Molecular Medicine, 2014, 33, 661-669.	4.0	33
198	Pathologic aspects of the hemorrhagic consequences of small vessel disease on the brain. , 0, , 29-41.		1
199	The link between large artery aging and cerebral small vessel disease. , 0, , 92-98.		2
200	Intrathecal Delivery of Mesenchymal Stromal Cells Protects the Structure of Altered Perineuronal Nets in SOD1 Rats and Amends the Course of ALS. Stem Cells, 2014, 32, 3163-3172.	3.2	73
201	Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 48, 319-353.	2.6	202
202	Matrix Metalloproteinases in Alzheimerâ€™s Disease and Concurrent Cerebral Microbleeds. Journal of Alzheimer's Disease, 2015, 48, 711-720.	2.6	71

#	Article	IF	Citations
203	Matrix Metalloproteinase in Blood-Brain Barrier Breakdown in Dementia. Journal of Alzheimer's Disease, 2016, 49, 893-903.	2.6	69
204	Spinal Glia Division Contributes to Conditioning Lesionâ€"Induced Axon Regeneration Into the Injured Spinal Cord. Journal of Neuropathology and Experimental Neurology, 2015, 74, 500-511.	1.7	14
205	Human immunoglobulinÂG suppresses the production of matrix metalloproteinaseâ€9 in peripheral blood mononuclear cells of patients with multiple sclerosis. Clinical and Experimental Neuroimmunology, 2015, 6, 281-288.	1.0	1
206	Matrix metalloproteinases in the mouse retina: a comparative study of expression patterns and MMP antibodies. BMC Ophthalmology, 2015, 15, 187.	1.4	25
207	Î²-Lapachone suppresses neuroinflammation by modulating the expression of cytokines and matrix metalloproteinases in activated microglia. Journal of Neuroinflammation, 2015, 12, 133.	7.2	77
208	Metalloproteinases and neurodegenerative diseases: pathophysiological and therapeutic perspectives. Metalloproteinases in Medicine, 0, , 39.	1.0	11
209	The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease. Current Alzheimer Research, 2015, 13, 53-67.	1.4	57
210	Fingolimod (FTY720-P) Does Not Stabilize the Bloodâ€"Brain Barrier under Inflammatory Conditions in an in Vitro Model. International Journal of Molecular Sciences, 2015, 16, 29454-29466.	4.1	10
211	Multifaceted role of matrix metalloproteinases (MMPs). Frontiers in Molecular Biosciences, 2015, 2, 19.	3.5	149
212	Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. Frontiers in Neurology, 2015, 6, 138.	2.4	44
213	Blood-brain barrier dysfunction in disorders of the developing brain. Frontiers in Neuroscience, 2015, 9, 40.	2.8	119
214	Nanoparticle-Based and Bioengineered Probes and Sensors to Detect Physiological and Pathological Biomarkers in Neural Cells. Frontiers in Neuroscience, 2015, 9, 480.	2.8	30
215	Investigation of enzyme-sensitive lipid nanoparticles for delivery of siRNA to blood–brain barrier and glioma cells. International Journal of Nanomedicine, 2015, 10, 5995.	6.7	49
216	Low-density lipoprotein receptor-related protein in metalloproteinase-mediated pathologies: recent insights. Metalloproteinases in Medicine, 2015, , 9.	1.0	2
217	Two-Dimensional Zymography Differentiates Gelatinase Isoforms in Stimulated Microglial Cells and in Brain Tissues of Acute Brain Injuries. PLoS ONE, 2015, 10, e0123852.	2.5	10
218	Decreased TNF Levels and Improved Retinal Ganglion Cell Survival in MMP-2 Null Mice Suggest a Role for MMP-2 as TNF Sheddase. Mediators of Inflammation, 2015, 2015, 1-13.	3.0	17
219	Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases. Mediators of Inflammation, 2015, 2015, 1-27.	3.0	154
220	Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body Inflammation in Bipolar Disorder?. Neural Plasticity, 2015, 2015, 1-12.	2.2	139

#	Article	IF	Citations
221	Improved Fracture Healing in Patients with Concomitant Traumatic Brain Injury: Proven or Not?. Mediators of Inflammation, 2015, 2015, 1-14.	3.0	53
222	Hypoxia-controlled matrix metalloproteinase-9 hyperexpression promotes behavioral recovery after ischemia. Neuroscience Bulletin, 2015, 31, 550-560.	2.9	23
223	Synthesis, X-ray crystal structure and biological evaluation of zinc(II)-dichlorido complexes with 9-deazahypoxathine derivatives. Inorganica Chimica Acta, 2015, 434, 67-73.	2.4	3
224	S100B blood levels and childhood trauma in adolescent inpatients. Journal of Psychiatric Research, 2015, 62, 14-22.	3.1	31
225	Elevated levels of plasma homocysteine, deficiencies in dietary folic acid and uracilâ€“DNA glycosylase impair learning in a mouse model of vascular cognitive impairment. Behavioural Brain Research, 2015, 283, 215-226.	2.2	31
226	New strategies for targeting matrix metalloproteinases. Matrix Biology, 2015, 44-46, 239-246.	3.6	89
227	Implication of matrix metalloproteinases in regulating neuronal disorder. Molecular Biology Reports, 2015, 42, 1-11.	2.3	29
228	Protease-degradable PEG-maleimide coating with on-demand release of IL-1Ra to improve tissue response to neural electrodes. Biomaterials, 2015, 44, 55-70.	11.4	55
229	Hypoxia-Induced Neuroinflammatory White-Matter Injury Reduced by Minocycline in SHR/SP. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1145-1153.	4.3	87
230	Validation of biomarkers in subcortical ischaemic vascular disease of the Binswanger type: approach to targeted treatment trials. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1324-1330.	1.9	31
231	Sequential Amyloid-Î² Degradation by the Matrix Metalloproteases MMP-2 and MMP-9. Journal of Biological Chemistry, 2015, 290, 15078-15091.	3.4	107
232	Peroxynitrite decomposition catalyst prevents matrix metalloproteinase-9 activation and neurovascular injury after hemoglobin injection into the caudate nucleus of rats. Neuroscience, 2015, 297, 182-193.	2.3	39
233	Matrix metalloproteinase-2 and -9 in the cerebellum of teleost fish: Functional implications for adult neurogenesis. Molecular and Cellular Neurosciences, 2015, 68, 9-23.	2.2	14
234	Immunology and Psychiatry. Current Topics in Neurotoxicity, 2015, , .	0.4	3
235	TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1121-1130.	3.0	23
236	Merging Allosteric and Active Site Binding Motifs: De novo Generation of Target Selectivity and Potency via Naturalâ€Productâ€Derived Fragments. ChemMedChem, 2015, 10, 451-454.	3.2	35
237	Extracellular matrix in the CNS. Neurology, 2015, 85, 1417-1427.	1.1	36
238	Amyloid Î² Oligomers Disrupt Bloodâ€“CSF Barrier Integrity by Activating Matrix Metalloproteinases. Journal of Neuroscience, 2015, 35, 12766-12778.	3.6	140

#	Article	IF	Citations
239	Interactions of Oxidative Stress and Neurovascular Inflammation in the Pathogenesis of Traumatic Brain Injury. Molecular Neurobiology, 2015, 51, 966-979.	4.0	333
240	Workflow for automated quantification of cerebromicrovascular gelatinase activity. Microvascular Research, 2015, 97, 19-24.	2.5	0
241	MMPs: a novel drug target for schizophrenia. Expert Opinion on Therapeutic Targets, 2015, 19, 77-85.	3.4	30
242	Aberrant Collagen Composition of the Trabecular Meshwork Results in Reduced Aqueous Humor Drainage and Elevated IOP in MMP-9 Null Mice. , 2016, 57, 5984.		43
243	MMP-3 Deficiency Alleviates Endotoxin-Induced Acute Inflammation in the Posterior Eye Segment. International Journal of Molecular Sciences, 2016, 17, 1825.	4.1	28
244	Matrix Metalloproteinase 9 in Epilepsy: The Role of Neuroinflammation in Seizure Development. Mediators of Inflammation, 2016, 2016, 1-14.	3.0	62
245	Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition. International Journal of Molecular Sciences, 2016, 17, 1562.	4.1	116
246	Red Grape Skin Polyphenols Blunt Matrix Metalloproteinase-2 and -9 Activity and Expression in Cell Models of Vascular Inflammation: Protective Role in Degenerative and Inflammatory Diseases. Molecules, 2016, 21, 1147.	3.8	39
247	Matrix Metalloproteinase-9 Expression in Calcified Human Aortic Valves. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 128-137.	1.2	22
248	Proteolytic processing of Neuregulin-1. Brain Research Bulletin, 2016, 126, 178-182.	3.0	37
249	Matrix metalloproteinases as promising regulators of axonal regrowth in the injured adult zebrafish retinotectal system. Journal of Comparative Neurology, 2016, 524, 1472-1493.	1.6	36
250	Microcystin-Leucine Arginine Causes Cytotoxic Effects in Sertoli Cells Resulting in Reproductive Dysfunction in Male Mice. Scientific Reports, 2016, 6, 39238.	3.3	35
251	Glycosylation of matrix metalloproteases and tissue inhibitors: present state, challenges and opportunities. Biochemical Journal, 2016, 473, 1471-1482.	3.7	49
252	Treatment with Trichuris suis soluble products during monocyteâ€toâ€macrophage differentiation reduces inflammatory responses through epigenetic remodeling. FASEB Journal, 2016, 30, 2826-2836.	0.5	25
253	Associations of Matrix Metalloproteinase-9 and Tissue Inhibitory Factor-1 Polymorphisms With Parkinson Disease in Taiwan. Medicine (United States), 2016, 95, e2672.	1.0	9
254	Plasma Matrix Metalloproteinases in Patients With Stroke During Intensive Rehabilitation Therapy. Archives of Physical Medicine and Rehabilitation, 2016, 97, 1832-1840.	0.9	17
255	Zbtb7c is a molecular â€˜offâ€™ and â€˜onâ€™ switch of Mmp gene transcription. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2016, 1859, 1429-1439.	1.9	8
256	Analysis of Mmp2-1306C/T and Timp2G-418C Polymorphisms with Relapsing Remitting Multiple Sclerosis. Journal of Investigative Medicine, 2016, 64, 1143-1147.	1.6	9

#	Article	IF	Citations
257	Role of MMP-2, MMP-7, MMP-9 and TIMP-2 in the development of recurrent depressive disorder. Journal of Affective Disorders, 2016, 205, 119-129.	4.1	33
258	Early role of vascular dysregulation on late-onset Alzheimerâ€™s disease based on multifactorial data-driven analysis. Nature Communications, 2016, 7, 11934.	12.8	833
259	Altered cerebrospinal fluid proteins in Smithâ€“Lemliâ€“Opitz syndrome patients. American Journal of Medical Genetics, Part A, 2016, 170, 2060-2068.	1.2	2
260	Matrix metalloproteinases in the brain and bloodâ€“brain barrier: Versatile breakers and makers. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1481-1507.	4.3	432
261	Brain ischaemia induces shedding of a <scp>BDNF</scp>â€scavenger ectodomain from <scp>TrkB</scp> receptors by excitotoxicity activation of metalloproteinases and Î³â€secretases. Journal of Pathology, 2016, 238, 627-640.	4.5	32
262	ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease. EBioMedicine, 2016, 9, 278-292.	6.1	40
263	Histamine induces the production of matrix metalloproteinase-9 in human astrocytic cultures via H1-receptor subtype. Brain Structure and Function, 2016, 221, 1845-1860.	2.3	12
264	Protective effect of naringin on 3-nitropropionic acid-induced neurodegeneration through the modulation of matrix metalloproteinases and glial fibrillary acidic protein. Canadian Journal of Physiology and Pharmacology, 2016, 94, 65-71.	1.4	32
265	Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients. Brain, Behavior, and Immunity, 2016, 52, 178-186.	4.1	26
266	Imaging of neuroinflammation in Alzheimer's disease, multiple sclerosis and stroke: Recent developments in positron emission tomography. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 425-441.	3.8	63
267	Matrix Metalloproteinase-Mediated Neuroinflammation in Vascular Cognitive Impairment of the Binswanger Type. Cellular and Molecular Neurobiology, 2016, 36, 195-202.	3.3	24
268	Anti-Inflammatory and Antioxidant Mechanism of Tangeretin in Activated Microglia. Journal of NeuroImmune Pharmacology, 2016, 11, 294-305.	4.1	64
269	Distinct roles for metalloproteinases during traumatic brain injury. Neurochemistry International, 2016, 96, 46-55.	3.8	35
270	Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions. Journal of Medicinal Chemistry, 2016, 59, 788-809.	6.4	55
271	Cardiovascular risk factors and small vessel disease of the brain: Blood pressure, white matter lesions, and functional decline in older persons. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 132-142.	4.3	118
272	Consensus statement for diagnosis of subcortical small vessel disease. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 6-25.	4.3	173
273	Dissecting the Contribution of Vascular Alterations and Aging to Alzheimerâ€™s Disease. Molecular Neurobiology, 2016, 53, 3793-3811.	4.0	48
274	Matrix Metalloproteinase-8 is a Novel Pathogenetic Factor in Focal Cerebral Ischemia. Molecular Neurobiology, 2016, 53, 231-239.	4.0	28

#	Article	IF	Citations
275	Matrix Metalloproteinases During Axonal Regeneration, a Multifactorial Role from Start to Finish. Molecular Neurobiology, 2017, 54, 2114-2125.	4.0	20
276	Gelatinase activity imaged by activatable cell-penetrating peptides in cell-based and inÂvivo models of stroke. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 188-200.	4.3	34
277	Ghrelin ameliorates bloodâ€“brain barrier disruption during systemic hypoxia. Experimental Physiology, 2017, 102, 376-382.	2.0	9
278	A systematic review on potential mechanisms of minocycline in kidney diseases. Pharmacological Reports, 2017, 69, 602-609.	3.3	28
279	Microglia preconditioned by oxygen-glucose deprivation promote functional recovery in ischemic rats. Scientific Reports, 2017, 7, 42582.	3.3	69
280	Hypoxic-Ischaemic Encephalopathy and the Blood-Brain Barrier in Neonates. Developmental Neuroscience, 2017, 39, 49-58.	2.0	49
281	Neuroinflammation in Bacterial Meningitis. , 2017, , 213-252.		3
282	Blood-Brain Barrier Permeability Is Exacerbated in Experimental Model of Hepatic Encephalopathy via MMP-9 Activation and Downregulation of Tight Junction Proteins. Molecular Neurobiology, 2018, 55, 3642-3659.	4.0	46
283	Zymography. Methods in Molecular Biology, 2017, , .	0.9	1
284	White matter injury induced by diabetes in acute stroke is clinically relevant: A preliminary study. Diabetes and Vascular Disease Research, 2017, 14, 40-46.	2.0	9
285	3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) produces edema due to BBB disruption induced by MMP-9 activation in rat hippocampus. Neuropharmacology, 2017, 118, 157-166.	4.1	23
286	Genome-wide RNA-seq of iPSC-derived motor neurons indicates selective cytoskeletal perturbation in Brownâ€“Vialetto disease that is partially rescued by riboflavin. Scientific Reports, 2017, 7, 46271.	3.3	22
287	Potential drug targets and treatment of schizophrenia. Inflammopharmacology, 2017, 25, 277-292.	3.9	22
288	Biomimetic Approaches for Bone Tissue Engineering. Tissue Engineering - Part B: Reviews, 2017, 23, 480-493.	4.8	69
289	Tea polyphenols ameliorates neural redox imbalance and mitochondrial dysfunction via mechanisms linking the key circadian regular Bmal1. Food and Chemical Toxicology, 2017, 110, 189-199.	3.6	40
290	Leukoaraiosis as an outcome predictor in the acute and subacute phases of stroke. Expert Review of Neurotherapeutics, 2017, 17, 963-975.	2.8	21
291	Metalloproteases in Adaptative Cell Responses. , 2017, , 121-142.		1
292	Matrix metalloproteinase-2 and â˜9 contribute to functional integrity and noise-induced damage to the blood-labyrinth-barrier. Molecular Medicine Reports, 2017, 16, 1731-1738.	2.4	23

#	Article	IF	Citations
293	Antibiotics-Induced Obesity: A Mitochondrial Perspective. Public Health Genomics, 2017, 20, 257-273.	1.0	16
294	In silico-based screen synergistic drug combinations from herb medicines: a case using Cistanche tubulosa. Scientific Reports, 2017, 7, 16364.	3.3	17
295	The multifaceted role of metalloproteinases in physiological and pathological conditions in embryonic and adult brains. Progress in Neurobiology, 2017, 155, 36-56.	5.7	34
296	Marine pharmacology: therapeutic targeting of matrix metalloproteinases in neuroinflammation. Drug Discovery Today, 2017, 22, 299-313.	6.4	14
297	Serum metalloproteinase 9 levels increase after generalized tonic-clonic seizures. Epilepsy Research, 2017, 129, 33-36.	1.6	22
298	Fc-saxatilin suppresses hypoxia-induced vascular leakage by regulating endothelial occludin expression. Thrombosis and Haemostasis, 2017, 117, 595-605.	3.4	3
299	Microglia and Monocytes/Macrophages Polarization Reveal Novel Therapeutic Mechanism against Stroke. International Journal of Molecular Sciences, 2017, 18, 2135.	4.1	297
300	Multifaceted Roles of Metzincins in CNS Physiology and Pathology: From Synaptic Plasticity and Cognition to Neurodegenerative Disorders. Frontiers in Cellular Neuroscience, 2017, 11, 178.	3.7	17
301	2-Chloroethanol Induced Upregulation of Matrix Metalloproteinase-2 in Primary Cultured Rat Astrocytes Via MAPK Signal Pathways. Frontiers in Neuroscience, 2016, 10, 593.	2.8	3
302	Endoplasmic Reticulum Malfunction in the Nervous System. Frontiers in Neuroscience, 2017, 11, 220.	2.8	21
303	Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer's disease. Neurobiology of Disease, 2017, 108, 307-323.	4.4	66
304	Role of Matrix Metalloproteinases in Brain Edema. , 2017, , 199-215.		2
305	Functional Activity of Matrix Metalloproteinases 2 and 9 in Tears of Patients With Glaucoma. , 2017, 58, BIO106.		44
306	Engineering Vascular Niche for Bone Tissue Regeneration. , 2017, , 517-529.		0
307	Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2018, 150, 87-101.	5.5	55
308	Looking for novel, brain-derived, peripheral biomarkers of neurological disorders. Neurologia I Neurochirurgia Polska, 2018, 52, 318-325.	1.2	38
309	Transcriptomics of aged Drosophila motor neurons reveals a matrix metalloproteinase that impairs motor function. Aging Cell, 2018, 17, e12729.	6.7	17
310	Substrate stiffness regulated migration and invasion ability of adenoid cystic carcinoma cells via RhoA/<scp>ROCK</scp> pathway. Cell Proliferation, 2018, 51, e12442.	5.3	25

#	Article	IF	Citations
311	Exploring in house glutamate inhibitors of matrix metalloproteinase-2 through validated robust chemico-biological quantitative approaches. Structural Chemistry, 2018, 29, 285-297.	2.0	16
312	Effects of Dexmedetomidine-Isoflurane versus Isoflurane Anesthesia on Brain Injury After Cardiac Valve Replacement Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 1581-1586.	1.3	8
313	3D-printed IFN-Î³-loading calcium silicate-Î²-tricalcium phosphate scaffold sequentially activates M1 and M2 polarization of macrophages to promote vascularization of tissue engineering bone. Acta Biomaterialia, 2018, 71, 96-107.	8.3	116
314	Cross-Talk between Glia, Neurons and Mast Cells in Neuroinflammation Associated with Parkinsonâ€™s Disease. Journal of NeuroImmune Pharmacology, 2018, 13, 100-112.	4.1	58
315	Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations. Translational Stroke Research, 2018, 9, 34-43.	4.2	45
316	Hypoxia-inducible factor-1Î± is involved in isoflurane-induced blood-brain barrier disruption in aged rats model of POCD. Behavioural Brain Research, 2018, 339, 39-46.	2.2	44
317	Matrix metalloproteinase 14 modulates diabetes and Alzheimerâ€™s disease cross-talk: a meta-analysis. Neurological Sciences, 2018, 39, 267-274.	1.9	7
318	Inflammatory Mediators in Neonatal Asphyxia and Infection. , 2018, , 1619-1639.		0
319	Divergent changes in the content and activity of MMP-26 and TIMP-4 in human umbilical cord tissues associated with preeclampsia. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 231, 48-53.	1.1	3
320	Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: A nanotechnological approach. International Journal of Pharmaceutics, 2018, 551, 339-361.	5.2	19
321	Pathophysiology of severe traumatic brain injury. Journal of Neurosurgical Sciences, 2018, 62, 542-548.	0.6	32
322	Chronic Cerebral Hypoperfusion Induces Alterations of Matrix Metalloproteinase-9 and Angiopoietin-2 Levels in the Rat Hippocampus. Experimental Neurobiology, 2018, 27, 299-308.	1.6	15
323	Association of the matrix metalloproteinase-3 polymorphisms rs679620 and rs3025058 with ischemic stroke risk: a meta-analysis. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 419-427.	2.2	5
324	Impaired Cerebral Perfusion in Multiple Sclerosis: Relevance of Endothelial Factors. Biomarker Insights, 2018, 13, 117727191877480.	2.5	14
325	Lanthanum Chloride Impairs the Blood-Brain Barrier Integrity by Reduction of Junctional Proteins and Upregulation of MMP-9 in Rats. Biological Trace Element Research, 2019, 187, 482-491.	3.5	24
326	The effect of age-related risk factors and comorbidities on white matter injury and repair after ischemic stroke. Neurobiology of Disease, 2019, 126, 13-22.	4.4	14
327	Cerebral Microvascular Injury: A Potentially Treatable Endophenotype of Traumatic Brain Injury-Induced Neurodegeneration. Neuron, 2019, 103, 367-379.	8.1	95
328	A Multimodal Approach to Stratification of Patients with Dementia: Selection of Mixed Dementia Patients Prior to Autopsy. Brain Sciences, 2019, 9, 187.	2.3	7

#	Article	IF	Citations
329	In silico screening of anticholinesterase alkaloids for cyclooxygenase-2 (COX-2) and matrix metalloproteinase 8 (MMP-8) inhibitory potentials as multi-target inhibitors of Alzheimerâ€™s disease. Medicinal Chemistry Research, 2019, 28, 1704-1717.	2.4	6
330	Plasma proteome in multiple sclerosis disease progression. Annals of Clinical and Translational Neurology, 2019, 6, 1582-1594.	3.7	21
331	Variable Surface Glycoprotein from Trypanosoma brucei Undergoes Cleavage by Matrix Metalloproteinases: An in silico Approach. Pathogens, 2019, 8, 178.	2.8	2
332	The Bloodâ€“Brain Barrier and Its Intercellular Junctions in Age-Related Brain Disorders. International Journal of Molecular Sciences, 2019, 20, 5472.	4.1	61
333	Association between abdominal hernia and the risk of subsequent dementia. Brain and Behavior, 2019, 9, e01434.	2.2	2
334	Bazedoxifene protects cerebral autoregulation after traumatic brain injury and attenuates impairments in bloodâ€“brain barrier damage: involvement of anti-inflammatory pathways by blocking MAPK signaling. Inflammation Research, 2019, 68, 311-323.	4.0	23
335	Shared Molecular Signatures Across Neurodegenerative Diseases and Herpes Virus Infections Highlights Potential Mechanisms for Maladaptive Innate Immune Responses. Scientific Reports, 2019, 9, 8795.	3.3	29
336	MMPs and ADAMs in neurological infectious diseases and multiple sclerosis. Cellular and Molecular Life Sciences, 2019, 76, 3097-3116.	5.4	46
337	Understanding aging effects on brain ischemia. Neurobiology of Disease, 2019, 126, 3-4.	4.4	3
338	Environmental Stressors May Drive Inflammation and Alter Neurocircuitry to Promote Suicidal Behavior. Current Psychiatry Reports, 2019, 21, 21.	4.5	8
339	Delayed Astrogliosis Associated with Reduced M1 Microglia Activation in Matrix Metalloproteinase 12 Knockout Mice during Theilerâ€™s Murine Encephalomyelitis. International Journal of Molecular Sciences, 2019, 20, 1702.	4.1	11
340	Gastrodin pretreatment alleviates rat brain injury caused by cerebral ischemic-reperfusion. Brain Research, 2019, 1712, 207-216.	2.2	31
341	Recent insights into natural product inhibitors of matrix metalloproteinases. MedChemComm, 2019, 10, 2024-2037.	3.4	15
342	Multifunctional hybrid sulfonamides as novel therapeutic agents for Alzheimerâ€™s disease. Future Medicinal Chemistry, 2019, 11, 3161-3178.	2.3	25
343	PR1P ameliorates neurodegeneration through activation of VEGF signaling pathway and remodeling of the extracellular environment. Neuropharmacology, 2019, 148, 96-106.	4.1	15
344	Comprehensive review of mechanisms of pathogenesis involved in Alzheimerâ€™s disease and potential therapeutic strategies. Progress in Neurobiology, 2019, 174, 53-89.	5.7	223
345	Elucidating Conserved Transcriptional Networks Underlying Pesticide Exposure and Parkinson's Disease: A Focus on Chemicals of Epidemiological Relevance. Frontiers in Genetics, 2018, 9, 701.	2.3	33
346	Monoclonal Antibody Targeting the Matrix Metalloproteinase 9 Prevents and Reverses Paclitaxel-Induced Peripheral Neuropathy in Mice. Journal of Pain, 2019, 20, 515-527.	1.4	44

#	Article	IF	Citations
347	Identification and Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-Risk Individuals: A Retrospective Cohort Analysis. Journal of Alzheimer's Disease, 2019, 67, 327-341.	2.6	32
348	Neuroinflammation, oxidative stress, and blood-brain barrier (BBB) disruption in acute Utah electrode array implants and the effect of deferoxamine as an iron chelator on acute foreign body response. Biomaterials, 2019, 188, 144-159.	11.4	51
349	Implication of Physiological and Biochemical Variables of Prognostic Importance in Lead Exposed Subjects. Archives of Environmental Contamination and Toxicology, 2020, 78, 329-336.	4.1	6
350	Increased Mmp/Reck Expression Ratio Is Associated with Increased Recognition Memory Performance in a Parkinsonâ€™s Disease Animal Model. Molecular Neurobiology, 2020, 57, 837-847.	4.0	1
351	Mixed dementia: Neglected clinical entity or nosographic artifice?. Journal of the Neurological Sciences, 2020, 410, 116662.	0.6	23
352	Serum matrix metallopeptidase-9 and tissue inhibitor of metalloproteinase-1 levels in autoimmune encephalitis. Brain and Development, 2020, 42, 264-269.	1.1	4
353	Lipopolysaccharide-Induced Matrix Metalloproteinase-9 Expression Associated with Cell Migration in Rat Brain Astrocytes. International Journal of Molecular Sciences, 2020, 21, 259.	4.1	21
354	New phosphazine and phosphazide derivatives as multifunctional ligands targeting acetylcholinesterase and Î²-Amyloid aggregation for treatment of Alzheimer's disease. Bioorganic Chemistry, 2020, 95, 103499.	4.1	12
355	Protection of blood-brain barrier as a potential mechanism for enriched environments to improve cognitive impairment caused by chronic cerebral hypoperfusion. Behavioural Brain Research, 2020, 379, 112385.	2.2	14
356	The Diverse Roles of TIMP-3: Insights into Degenerative Diseases of the Senescent Retina and Brain. Cells, 2020, 9, 39.	4.1	25
357	Apitherapy for Parkinsonâ€™s Disease: A Focus on the Effects of Propolis and Royal Jelly. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-18.	4.0	32
358	Interaction between genetic factors, Porphyromonas gingivalis and microglia to promote Alzheimerâ€™s disease. Journal of Oral Microbiology, 2020, 12, 1820834.	2.7	16
359	Pharmacological Effects of Salvianolic Acid B Against Oxidative Damage. Frontiers in Pharmacology, 2020, 11, 572373.	3.5	63
360	Pristimerin Inhibits MMP-9 Expression and Cell Migration Through Attenuating NOX/ROS-Dependent NF-ÎºB Activation in Rat Brain Astrocytes Challenged with LPS . Journal of Inflammation Research, 2020, Volume 13, 325-341.	3.5	32
361	Angiostrongylus cantonensis infection induces MMP-9 and causes tight junction protein disruption associated with Purkinje cell degeneration. Parasitology Research, 2020, 119, 3433-3441.	1.6	2
362	Matrix metalloproteinase-degraded type I collagen is associated with APOE/TOMM40 variants and preclinical dementia. Neurology: Genetics, 2020, 6, e508.	1.9	6
363	Locus Coeruleus and neurovascular unit: From its role in physiology to its potential role in Alzheimerâ€™s disease pathogenesis. Journal of Neuroscience Research, 2020, 98, 2406-2434.	2.9	38
364	A Hierarchical Structured Ultrafine Fiber Device for Preventing Postoperative Recurrence and Metastasis of Breast Cancer. Advanced Functional Materials, 2020, 30, 2004851.	14.9	36

#	Article	IF	Citations
365	Mechanobiology of the brain in ageing and Alzheimer's disease. European Journal of Neuroscience, 2021, 53, 3851-3878.	2.6	61
366	Serum tissue inhibitor of metalloproteinaseâ€1 and risk of cognitive impairment after acute ischaemic stroke. Journal of Cellular and Molecular Medicine, 2020, 24, 7470-7478.	3.6	12
367	Matrix Metalloproteinases as New Targets in Alzheimerâ€™s Disease: Opportunities and Challenges. Journal of Medicinal Chemistry, 2020, 63, 10705-10725.	6.4	42
368	Heavy Metal-Induced Cerebral Small Vessel Disease: Insights into Molecular Mechanisms and Possible Reversal Strategies. International Journal of Molecular Sciences, 2020, 21, 3862.	4.1	30
369	Identification of Novel Alzheimerâ€™s Disease Loci Using Sex-Specific Family-Based Association Analysis of Whole-Genome Sequence Data. Scientific Reports, 2020, 10, 5029.	3.3	31
370	Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database. Journal of the Neurological Sciences, 2020, 416, 116989.	0.6	18
371	Increased prolidase activity in Alzheimerâ€™s dementia: A case-control study. Asian Journal of Psychiatry, 2020, 53, 102242.	2.0	2
372	Tightening the retinal glia limitans attenuates neuroinflammation after optic nerve injury. Glia, 2020, 68, 2643-2660.	4.9	8
373	Plasma dilution improves cognition and attenuates neuroinflammation in old mice. GeroScience, 2021, 43, 1-18.	4.6	46
374	Discovery of 7-aminophenanthridin-6-one as a new scaffold for matrix metalloproteinase inhibitors with multitarget neuroprotective activity. European Journal of Medicinal Chemistry, 2021, 210, 113061.	5.5	6
375	Neuroprotective potential of isothiocyanates in an in vitro model of neuroinflammation. Inflammopharmacology, 2021, 29, 561-571.	3.9	23
376	Cypermethrin Induces the Activation of Rat Primary Microglia and Expression of Inflammatory Proteins. Journal of Molecular Neuroscience, 2021, 71, 1275-1283.	2.3	3
377	Proteolytic cleavage of proBDNF to mBDNF in neuropsychiatric and neurodegenerative diseases. Brain Research Bulletin, 2021, 166, 172-184.	3.0	37
378	Cerebrospinal fluid cytokines and metalloproteinases in cerebral amyloid angiopathyâ€related inflammation. Acta Neurologica Scandinavica, 2021, 143, 450-457.	2.1	8
379	Metalloproteinases genes and their relationship with depression. , 2021, , 59-67.		0
381	Effect of Elaeagnus umbellata (Thunb.) fruit extract on H₂O₂-induced oxidative and inflammatory responses in normal fibroblast cells. PeerJ, 2021, 9, e10760.	2.0	6
382	A method of purifying alpha-synuclein in E.Âcoli without chromatography. Heliyon, 2021, 7, e05874.	3.2	5
383	DNMT3b SUMOylation Mediated MMP-2 Upregulation Contribute to Paclitaxel Induced Neuropathic Pain. Neurochemical Research, 2021, 46, 1214-1223.	3.3	5

#	Article	IF	Citations
384	The Neurovascular Unit Dysfunction in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 2022.	4.1	65
385	Hepatitis Bâ€“Induced IL8 Promotes Hepatocellular Carcinoma Venous Metastasis and Intrahepatic Treg Accumulation. Cancer Research, 2021, 81, 2386-2398.	0.9	31
386	MiR-874-3p plays a protective role in intervertebral disc degeneration by suppressing MMP2 and MMP3. European Journal of Pharmacology, 2021, 895, 173891.	3.5	11
387	Ginsenoside Rg1 ameliorates bloodâ€“brain barrier disruption and traumatic brain injury via attenuating macrophages derived exosomes miR-21 release. Acta Pharmaceutica Sinica B, 2021, 11, 3493-3507.	12.0	75
388	Insoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimerâ€™s Disease Brains. International Journal of Molecular Sciences, 2021, 22, 3654.	4.1	16
389	Multiple Particle Tracking Detects Changes in Brain Extracellular Matrix and Predicts Neurodevelopmental Age. ACS Nano, 2021, 15, 8559-8573.	14.6	10
390	Expression of Drosophila Matrix Metalloproteinases in Cultured Cell Lines Alters Neural and Glial Cell Morphology. Frontiers in Cell and Developmental Biology, 2021, 9, 610887.	3.7	1
391	Role of P2X7 Receptors in Immune Responses During Neurodegeneration. Frontiers in Cellular Neuroscience, 2021, 15, 662935.	3.7	24
392	Mycobacterium tuberculosis causes a leaky bloodâ€brain barrier and neuroinflammation in the prefrontal cortex and cerebellum regions of infected mice offspring. International Journal of Developmental Neuroscience, 2021, 81, 428-437.	1.6	5
393	Thrombospondinâ€4 promotes bladder cancer cell migration and invasion via MMP2 production. Journal of Cellular and Molecular Medicine, 2021, 25, 6046-6055.	3.6	11
394	Microglia in the Pathophysiology of Hemorrhagic Stroke and the Relationship Between Microglia and Pain After Stroke: A Narrative Review. Pain and Therapy, 2021, 10, 927-939.	3.2	12
395	A synergy between the catalytic and structural Zn(II) ions and the enzyme and substrate dynamics underlies the structureâ€“function relationships of matrix metalloproteinase collagenolysis. Journal of Biological Inorganic Chemistry, 2021, 26, 583-597.	2.6	8
396	Carnosine Protects against Cerebral Ischemic Injury by Inhibiting Matrix-Metalloproteinases. International Journal of Molecular Sciences, 2021, 22, 7495.	4.1	16
397	Serum matrix metallopeptidase-9 and tissue inhibitor of metalloproteinase-1 levels may predict response to adrenocorticotropic hormone therapy in patients with infantile spasms. Brain and Development, 2022, 44, 114-121.	1.1	1
398	The effect of surgery on the levels of matrix metalloproteinases in patients with inguinal hernia. Physiological Research, 2021, 70, 627-634.	0.9	2
399	Neuroprotective Action of Multitarget 7-Aminophenanthridin-6(5H)-one Derivatives against Metal-Induced Cell Death and Oxidative Stress in SN56 Cells. ACS Chemical Neuroscience, 2021, 12, 3358-3372.	3.5	6
400	Potent therapeutic targets for treatment of Alzheimer's disease: Amyloid degrading enzymes. Bulletin of the Korean Chemical Society, 2021, 42, 1419-1429.	1.9	7
401	Mild blast wave exposure produces intensity-dependent changes in MMP2 expression patches in rat brains â€“ Findings from different blast severities. Brain Research, 2021, 1767, 147541.	2.2	2

#	Article	IF	Citations
402	Ratiometric magnetic resonance imaging: Contrast agent design towards better specificity and quantification. Coordination Chemistry Reviews, 2021, 447, 214150.	18.8	14
403	Perivascular Inflammation and Extracellular Matrix Alterations in Blood-Brain Barrier Dysfunction and Epilepsy. Agents and Actions Supplements, 2021, , 71-106.	0.2	1
404	The matrix metalloproteinase inhibitor IPR-179 has antiseizure and antiepileptogenic effects. Journal of Clinical Investigation, 2021, 131, .	8.2	35
405	Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives. International Journal of Molecular Sciences, 2021, 22, 1413.	4.1	76
406	Brain Edema in Neurological Diseases. Advances in Neurobiology, 2011, , 125-168.	1.8	2
407	Examination of Gelatinase Isoforms in Rodent Models of Acute Neurodegenerative Diseases Using Two-Dimensional Zymography. Methods in Molecular Biology, 2017, 1626, 147-155.	0.9	2
408	Immune System Related Markers: Changes in childhood Neuropsychiatry Disorders Cause and Consequence. Current Topics in Neurotoxicity, 2015, , 161-199.	0.4	3
409	Inflammatory Mediators in Neonatal Asphyxia and Infection. , 2016, , 1-20.		2
411	Contributions of Drug Transporters to Blood-Brain Barriers. Advances in Experimental Medicine and Biology, 2019, 1141, 407-466.	1.6	10
412	Berberine Attenuates Experimental Autoimmune Encephalomyelitis in C57 BL/6 Mice. PLoS ONE, 2010, 5, e13489.	2.5	91
413	Selective Inhibition of Matrix Metalloproteinase-9 Attenuates Secondary Damage Resulting from Severe Traumatic Brain Injury. PLoS ONE, 2013, 8, e76904.	2.5	95
414	Inhibitory Effect of Aqueous Extracts from Marine Sponges on the Activity and Expression of Gelatinases A (MMP-2) and B (MMP-9) in Rat Astrocyte Cultures. PLoS ONE, 2015, 10, e0129322.	2.5	13
415	GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinsonâ€™s Disease and Lewy Body Dementia. PLoS ONE, 2016, 11, e0149349.	2.5	29
416	Cell Type-Specific Oxidative Stress Genomic Signatures in the Globus Pallidus of Dopamine-Depleted Mice. Journal of Neuroscience, 2020, 40, 9772-9783.	3.6	14
417	Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases. Current Pharmaceutical Design, 2014, 20, 2993-3018.	1.9	22
418	Therapeutic Potential of Phosphodiesterase Inhibitors for Endothelial Dysfunction- Related Diseases. Current Pharmaceutical Design, 2020, 26, 3633-3651.	1.9	5
419	The Infectious Etiology of Alzheimerâ€™s Disease. Current Neuropharmacology, 2017, 15, 996-1009.	2.9	263
420	Smoking and Endothelial Dysfunction. Current Vascular Pharmacology, 2019, 18, 1-11.	1.7	51

#	Article	IF	Citations
421	Stem Cells in Amyotrophic Lateral Sclerosis: Motor Neuron Protection or Replacement?. CNS and Neurological Disorders - Drug Targets, 2010, 9, 314-324.	1.4	21
422	The MMP-2/TIMP-2 System in Alzheimer Disease. CNS and Neurological Disorders - Drug Targets, 2020, 19, 402-416.	1.4	14
423	Administration of ghrelin associated with decreased expression of matrix metalloproteinase-9 following normobaric systemic hypoxia in the brain. Endocrine Regulations, 2018, 52, 152-158.	1.3	2
424	Effect of tanshinone â…¡ A on MMP-2 and iNOS expression and free radical release in hippocampus of rat Alzheimer's disease model. Academic Journal of Second Military Medical University, 2010, 30, 380-384.	0.0	7
425	Vascular Dysfunction in Brain Hemorrhage: Translational Pathways to Developing New Treatments from Old Targets. Journal of Neurology & Neurophysiology, 2011, 01, .	0.1	11
426	Population genetic variations of the matrix metalloproteinases-3 gene revealed hypoxia adaptation in domesticated yaks (Bos grunniens). Asian-Australasian Journal of Animal Sciences, 2019, 32, 1801-1808.	2.4	2
427	Stem Cell Based Therapy for Muscular Dystrophies: Cell Types and Environmental Factors Influencing Their Efficacy. , 0, , .		2
428	Relationship between Cerebrospinal Fluid Matrix Metalloproteinases Levels and Brain Amyloid Deposition in Mild Cognitive Impairment. Biomolecules, 2021, 11, 1496.	4.0	5
429	Cases for 3D Cultures in Drug Discovery. , 2010, , 289-305.		0
430	Chemical Microenvironmental Factors. , 2010, , 97-119.		0
431	Identifying Vascular Targets to Treat Hemorrhagic Stroke. , 2012, , 37-55.		0
432	Neuroimaging of White Matter Injury: A Multimodal Approach to Vascular Disease. , 2014, , 67-90.		0
433	Immunopathogenesis of Bacterial Meningitis. , 2014, , 387-404.		0
434	Bloodâ€“Brain Barrier. , 2014, , 434-440.		0
435	Small Vessel Disease of the Brain and Stroke: Association with Clinic and Ambulatory Blood Pressure. Hypertension Journal, 2016, 2, 65-73.	0.1	0
436	Evaluation of Doxycycline Toxicological effects on Japanese Quail (Coturnix Coturnix Japonica) on: Behavioral Patterns and Histopathological findings. Alexandria Journal of Veterinary Sciences, 2018, 59, 91.	0.1	1
437	Gelatinase-Mediated Impairment of Microvascular Beds in Cerebral Ischemia and Reperfusion Injury. Springer Series in Translational Stroke Research, 2018, , 1-14.	0.1	1
438	Women and Chest Pain: Recognizing the Different Faces of Angina in the Emergency Department. Yale Journal of Biology and Medicine, 2016, 89, 227-38.	0.2	11

#	Article	IF	Citations
439	Fisetin inhibits epidermal growth factor-induced migration of ARPE-19 cells by suppression of AKT activation and Sp1-dependent MMP-9 expression. Molecular Vision, 2017, 23, 900-910.	1.1	18
440	CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease. Neurology: Genetics, 2021, 7, e633.	1.9	12
441	Metalloproteinases and their inhibitors in neurological disease. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, , 1.	3.0	5
442	Immune response and pathogen invasion at the choroid plexus in the onset of cerebral toxoplasmosis. Journal of Neuroinflammation, 2022, 19, 17.	7.2	13
443	Plasma MMP-9 Levels as the Future Risk of Conversion to Dementia in ApoE4-Positive MCI Patients: Investigation Based on the Alzheimerâ€™s Disease Neuroimaging Initiative Database. journal of prevention of Alzheimer's disease, The, 2022, 9, 331-337.	2.7	0
444	Effects of the Nature of Metal Ion, Protein and Substrate on the Catalytic Center in Matrix Metalloproteinaseâ€1: Insights from Multilevel MD, QM/MM and QM Studies. ChemPhysChem, 2022, 23, e202100680.	2.1	2
445	Neuroprotective effects of carvacrol against cadmium-induced neurotoxicity in rats: role of oxidative stress, inflammation and apoptosis. Metabolic Brain Disease, 2022, 37, 1259-1269.	2.9	10
446	Identification of allosteric fingerprints of alpha-synuclein aggregates in matrix metalloprotease-1 and substrate-specific virtual screening with single molecule insights. Scientific Reports, 2022, 12, 5764.	3.3	2
447	Insights into the anticancer activity of chiral alkylidene-Î²-lactams and alkylidene-Î³-lactams: Synthesis and biological investigation. Bioorganic and Medicinal Chemistry, 2022, 63, 116738.	3.0	3
448	Impact of metabolic disorders on the structural, functional, and immunological integrity of the bloodâ€brain barrier: Therapeutic avenues. FASEB Journal, 2022, 36, e22107.	0.5	16
449	Kaempferol prevents the activation of complement C3 protein and the generation of reactive A1 astrocytes that mediate rat brain degeneration induced by 3-nitropropionic acid. Food and Chemical Toxicology, 2022, 164, 113017.	3.6	16
450	Dolichoectasia: a brain arterial disease with an elusive treatment. Neurological Sciences, 2022, 43, 4901-4908.	1.9	7
452	Mechanotransduction: Exploring New Therapeutic Avenues in Central Nervous System Pathology. Frontiers in Neuroscience, 2022, 16, 861613.	2.8	10
453	Maresin 1 improves cognitive decline and ameliorates inflammation and blood-brain barrier damage in rats with chronic cerebral hypoperfusion. Brain Research, 2022, 1788, 147936.	2.2	8
454	Decreased levels of cytokines implicate altered immune response in plasma of moderate-stage Alzheimerâ€™s disease patients. Neuroscience Letters, 2022, 786, 136799.	2.1	3
455	Sex-Related Differences of Matrix Metalloproteinases (MMPs): New Perspectives for These Biomarkers in Cardiovascular and Neurological Diseases. Journal of Personalized Medicine, 2022, 12, 1196.	2.5	9
456	Evaluation of decompressive craniectomy in mice after severe traumatic brain injury. Frontiers in Neurology, 0, 13, .	2.4	1
457	The emerging role of furin in neurodegenerative and neuropsychiatric diseases. Translational Neurodegeneration, 2022, 11, .	8.0	19

#	Article	IF	Citations
458	The barrier and interface mechanisms of the brain barrier, and brain drug delivery. Brain Research Bulletin, 2022, 190, 69-83.	3.0	19
459	Neuroinflammation. , 2023, , 87-106.		0
460	Animal models for vascular cognitive impairment. , 2023, , 107-120.		0
461	Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinsonâ€™s disease. Frontiers in Aging Neuroscience, 0, 14, .	3.4	3
462	Mechanism of the Early Catalytic Events in the Collagenolysis by Matrix Metalloproteinaseâ€1. ChemPhysChem, 2023, 24, .	2.1	4
463	Matrix Metalloproteinases and Glaucoma. Biomolecules, 2022, 12, 1368.	4.0	6
464	Willis Lecture: Biomarkers for Inflammatory White Matter Injury in Binswanger Disease Provide Pathways to Precision Medicine. Stroke, 2022, 53, 3514-3523.	2.0	2
465	Neurocognitive trajectory and proteomic signature of inherited risk for Alzheimerâ€™s disease. PLoS Genetics, 2022, 18, e1010294.	3.5	3
467	Bioresponsive Nanomaterials for CNS Disease. , 2022, , 189-227.		0
468	The uniqueness and superiority of energy utilization in yaks compared with cattle in the highlands: A review. Animal Nutrition, 2023, 12, 138-144.	5.1	4
469	Matrixmetalloproteinase-9 gene polymorphism (rs 17576) increases the risk of depressive symptoms in bipolar disorder. Journal of Neurosciences in Rural Practice, 0, 13, 691-695.	0.8	1
470	Apoptosis-associated speck-like protein containing a CARD-mediated release of matrix metalloproteinase 10 stimulates a change in microglia phenotype. Frontiers in Molecular Neuroscience, 0, 15, .	2.9	0
471	Sex differences in Alzheimerâ€™s disease: plasma MMP-9 and markers of disease severity. Alzheimer's Research and Therapy, 2022, 14, .	6.2	6
472	MMP-12 knockdown prevents secondary brain damage after ischemic stroke in mice. Neurochemistry International, 2022, 161, 105432.	3.8	4
473	Marine Natural Products from the Russian Pacific as Sources of Drugs for Neurodegenerative Diseases. Marine Drugs, 2022, 20, 708.	4.6	8
474	Biomechanical forces in the aged brain: Relationship to AD. Life Sciences, 2023, 312, 121237.	4.3	2
475	Ginsenoside Rb1 from Panax notoginseng Suppressed TNF-Î±-Induced Matrix Metalloproteinase-9 via the Suppression of Double-Strand RNA-Dependent Protein Kinase (PKR)/NF-ÎºB Pathway. Molecules, 2022, 27, 8050.	3.8	3
476	Blood-brain barrier disruption measured by albumin index correlates with inflammatory fluid biomarkers. Journal of Cerebral Blood Flow and Metabolism, 2023, 43, 712-721.	4.3	7

#	Article	IF	Citations
477	Bloodâ€“Brain Barrier Disruption and Its Involvement in Neurodevelopmental and Neurodegenerative Disorders. International Journal of Molecular Sciences, 2022, 23, 15271.	4.1	10
478	Metal Complexes as Promising Matrix Metalloproteinases Regulators. International Journal of Molecular Sciences, 2023, 24, 1258.	4.1	5
479	Serum levels of matrix metalloproteinase 2 and its inhibitor after tonic-clonic seizures. Epilepsy Research, 2023, 192, 107115.	1.6	0
480	Biodegradable bilayer hydrogel membranes loaded with bazedoxifene attenuate bloodâ€“spinal cord barrier disruption via the NF-ÎºB pathway after acute spinal cord injury. Acta Biomaterialia, 2023, 159, 140-155.	8.3	4
481	Long-Term Neuromodulatory Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Plasmatic Matrix Metalloproteinases (MMPs) Levels and Visuospatial Abilities in Mild Cognitive Impairment (MCI). International Journal of Molecular Sciences, 2023, 24, 3231.	4.1	8
482	Neurotherapeutic efficacy of loaded sulforaphane on iron oxide nanoparticles against cuprizone-induced neurotoxicity: role of MMP-9 and S100Î². Toxicology Mechanisms and Methods, 2023, 33, 463-479.	2.7	0
483	MMP2 is a immunotherapy related biomarker and correlated with cancer-associated fibroblasts infiltrate in melanoma. Cancer Cell International, 2023, 23, .	4.1	3
484	Vascular Effects on Cerebrovascular Permeability and Neurodegeneration. Biomolecules, 2023, 13, 648.	4.0	5
485	Expression of matrix metalloproteinase in patients with Alzheimer and mechanism of huangqi granule (astragalus saponins) intervention. Materials Express, 2023, 13, 253-259.	0.5	0
486	Comparative Investigation of Expression of Glutamatergic and GABAergic Genes in the Rat Hippocampus after Focal Brain Ischemia and Central LPS Administration. Biochemistry (Moscow), 2023, 88, 539-550.	1.5	0
487	Sex-specific associations of matrix metalloproteinases in Alzheimerâ€™s disease. Biology of Sex Differences, 2023, 14, .	4.1	1
488	Matrix metalloproteinases are associated with brain atrophy in cognitively unimpaired individuals. Neurobiology of Aging, 2023, 131, 11-23.	3.1	2
489	Interactions between astrocytes and extracellular matrix structures contribute to neuroinflammation-associated epilepsy pathology. Frontiers in Molecular Medicine, 0, 3, .	1.9	0
490	Changes in the Midbrain Neurobiological Responses to Lithium Chloride under Inflammatory Conditions. Neurochemical Journal, 2023, 17, 101-110.	0.5	0
491	CSF proteomics in autosomal dominant Alzheimerâ€™s disease highlights parallels with sporadic disease. Brain, 2023, 146, 4495-4507.	7.6	5
492	The neurovascular unit in healthy and injured spinal cord. Journal of Cerebral Blood Flow and Metabolism, 2023, 43, 1437-1455.	4.3	2
493	Î²-hydroxybutyrate attenuates demyelination, modulates microglial phenotype and supports blood-brain barrier integrity in a cuprizone-induced mouse model of demyelination. Journal of Functional Foods, 2023, 105, 105580.	3.4	1
494	Neurobiochemical characteristics of arginine-rich peptides explain their potential therapeutic efficacy in neurodegenerative diseases. Neuropeptides, 2023, 101, 102356.	2.2	2

#	Article	IF	Citations
495	Structural, computational and in silico studies of 4-bromo-3-flurobenzonitrile as anti-Alzheimer and anti-Parkinson agents. Journal of Biomolecular Structure and Dynamics, 0, , 1-25.	3.5	1
496	Time-dependent dual effect of microglia in ischemic stroke. Neurochemistry International, 2023, 169, 105584.	3.8	3
497	Associations of Glucose Metabolism Status with Brain Macro- and Microstructure: Findings from the UK Biobank. Journal of Clinical Endocrinology and Metabolism, 0, , .	3.6	1
498	Role of cytokines and reactive oxygen species in brain aging. Mechanisms of Ageing and Development, 2023, 214, 111855.	4.6	3
499	Single-cell analysis of dorsal root ganglia reveals metalloproteinase signaling in satellite glial cells and pain. Brain, Behavior, and Immunity, 2023, 113, 401-414.	4.1	3
500	Gelatin Zymography Can Be Performed on Fixed Brain Tissue. Journal of Histochemistry and Cytochemistry, 2023, 71, 481-493.	2.5	0
501	TIMP-1 Protects Tight Junctions of Brain Endothelial Cells From MMP-Mediated Degradation. Pharmaceutical Research, 2023, 40, 2121-2131.	3.5	0
502	Brain organoids for hypoxic-ischemic studies: from bench to bedside. Cellular and Molecular Life Sciences, 2023, 80, .	5.4	0
503	Redox-active endosomes mediate Î±5Î²1 integrin signaling and promote chondrocyte matrix metalloproteinase production in osteoarthritis. Science Signaling, 2023, 16, .	3.6	2
504	Protease detection in the biosensor era: A review. Biosensors and Bioelectronics, 2024, 244, 115788.	10.1	0
505	Bloodâ€“Brain Barrier Breakdown in Alzheimerâ€™s Disease: Mechanisms and Targeted Strategies. International Journal of Molecular Sciences, 2023, 24, 16288.	4.1	1
507	Minding the Gap: Exploring Neuroinflammatory and Microglial Sex Differences in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2023, 24, 17377.	4.1	0
508	Crosstalk Between Matrix Metalloproteinases and Their Inducer EMMPRIN/CD147: a Promising Therapeutic Target for Intracerebral Hemorrhage. Translational Stroke Research, 0, , .	4.2	1
509	Protective effect of a hydromethanolic extract from Fraxinus excelsior L. bark against a rat model of aluminum chloride-induced Alzheimer's disease: Relevance to its anti-inflammatory and antioxidant effects. Journal of Ethnopharmacology, 2024, 323, 117708.	4.1	0
510	Matrix metalloproteinases at a glance. Journal of Cell Science, 2024, 137, .	2.0	0
511	A Brain-Protective Sterol from Soft Coral Inhibits Lipopolysaccharide-Induced Matrix Metalloproteinase-9-Mediated Astrocytic Migration. Biomedicines, 2024, 12, 226.	3.2	0
512	Fluid biomarkers in cerebral amyloid angiopathy. Frontiers in Neuroscience, 0, 18, .	2.8	0
513	System biology approaches to identify hub genes linked with ECM organization and inflammatory signaling pathways in schizophrenia pathogenesis. Heliyon, 2024, 10, e25191.	3.2	0

#	Article	IF	Citations
514	Cellular junction dynamics and Alzheimerâ€™s disease: a comprehensive review. Molecular Biology Reports, 2024, 51, .	2.3	0
515	An Update of Kaempferol Protection against Brain Damage Induced by Ischemia-Reperfusion and by 3-Nitropropionic Acid. Molecules, 2024, 29, 776.	3.8	0